TLR9 and neoplasm: Previously, treatment of A20 tumors with intratumorally injected synthetic oligodeoxynucleotides (ODNs) containing unmethylated CpG motifs (CpG), which are strong activators of toll-like receptor 9, was shown to have similar clinical efficacy as G100, however, knockout of TLR9 in tumor cells or the host animal reduced sensitivity to CpG but did not eliminate it completely (31).